To know if the combination (SMAD3i + BRAFi) could be broadly used to eradicate persister cells emerging in response to BRAFi treatment, we selected three melanoma cell lines in function of SMAD3 expression levels (Fig 5L). This evidence concerns the gene SMAD3 and melanoma.